肿瘤细胞治疗研究
英文原题：CAR-T therapy for ovarian cancer: Recent advances and future directions.
卵巢癌（OC）是一种常见的妇科肿瘤，死亡率高，常规治疗难以控制其进展，且容易复发。
卵巢癌（OC）是一种常见妇科肿瘤，死亡率高，常规治疗难以控制其进展且容易复发。近期研究已将 OC 认定为可被宿主免疫系统识别的免疫原性肿瘤。目前正在评估 OC 免疫疗法，但免疫检查点抑制剂等方法疗效有限。过继细胞疗法是一种替代方案，其中 CAR（嵌合抗原受体）T 细胞疗法已用于血液系统恶性肿瘤临床治疗。此外，CAR-NK 和 CAR-巨噬细胞（CAR-M）在实体瘤治疗中也显示出巨大潜力。本文讨论 CAR-T 治疗 OC 的临床前和临床研究最新进展，介绍研究人员为实现有效 OC 免疫治疗而改造 CAR 结构所作的努力，以及 CAR-NK 和 CAR-M 的研究现状，并重点介绍可利用 CAR 介导的过继细胞疗法改善 OC 患者生存的新兴治疗机会。
Ovarian cancer (OC) is a common gynecological tumor with high mortality, which is difficult to control its progression with conventional treatments and is prone to recurrence. Recent studies have identified OC as an immunogenic tumor that can be recognized by the host immune system. Immunotherapy for OC is being evaluated, but approaches such as immune checkpoint inhibitors have limited efficacy, adoptive cell therapy is an alternative therapy, in which CAR(chimeric antigen receptor)-T therapy has been applied to the clinical treatment of hematological malignancies. In addition, CAR-NK and CAR-macrophage (CAR-M) have also shown great potential in the treatment of solid tumors. Here, we discuss recent advances in preclinical and clinical studies of CAR-T for OC treatment, introduce the efforts made by researchers to modify the structure of CAR in order to achieve effective OC immunotherapy, as well as the research status of CAR-NK and CAR-M, and highlight emerging therapeutic opportunities that can be utilized to improve the survival of patients with OC using CAR-based adoptive cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
